INDUCTION THERAPY IN RENAL TRANSPLANTATION WITH ANTITHYMOCYTE GLOBULIN AND BASILIXIMAB- A SINGLE CENTRE RETROSPECTIVE STUDY

Journal Title: Journal of Evidence Based Medicine and Healthcare - Year 2018, Vol 5, Issue 52

Abstract

BACKGROUND Renal transplantation is the best available form of renal replacement therapy. Induction therapy pre-transplant reduces the incidence of graft rejections. We present a retrospective study comparing different induction methods in living donor kidney transplantation in our institute. MATERIALS AND METHODS We analysed 423 live kidney transplant recipients of our center from Dec 2010 to Nov 2015, 344 of whom received basiliximab as induction and 79 r-ATG as induction. Primary outcomes like patient survival and graft survival, secondary outcomes like graft rejections, infections, PTDM, recurrence of disease were compared. RESULTS 5yr patient survival rates were observed to be 91% and 88% respectively whereas graft survival rates were 93% and 86% respectively for ATG and basiliximab. Incidence of rejections was similar (p=0.867). Cellular rejections were more common with basiliximab (7.9% vs. 3.8%) but statistically not significant (P=0.498). Infections in the post-operative period were more common in r-ATG arm especially LRTI (P=0.011) and diarrhoeal episodes (P=0.005). Incidence of cytopenias was more in rATG arm during hospital stay (10.1 vs. 2.6% P=0.002) and also the later followup period (25 vs. 12.4% P<0.001). Incidence of PTDM was more in basiliximab (33.8% vs. 22.8%) arm but not significant (P=0.061). CONCLUSION ATG and basiliximab are non-inferior to one another as induction therapy. ATG is effective in high immunological risk groups with equivalent graft and patient survival with increased risk of Lower respiratory tract infections and diarrhoea in immediate post-transplant periods and increased risk for cytopenias compared to basiliximab. Basiliximab has slightly increased risk of post-transplant diabetes mellitus. Careful selection of the agent in an individual based on risk rather than a question of efficacy of agents is the key to successful transplantation.

Authors and Affiliations

Hareesh M. V. K, Sharma R. K.

Keywords

Related Articles

THE ILL EFFECTS IN THE ORAL HEALTH AMONG THE ADULTS DUE TO THE CONSUMPTION OF AERATED DRINKS

BACKGROUND Excessive consumption of carbonated soft drink is detrimental to oral and general health and the popularity of the aerated drinks among adults has grown exponentially. This study aims at determining the preval...

NOT ALL FOREIGN BODIES OF UPPER DIGESTIVE TRACT ARE ACCIDENTAL

To give the message that a sharp foreign body in the upper gastrointestinal tract in a female child is to be seen with caution as it could be a case of infanticidal attempt. CASE REPORT: A two and half month old baby pre...

ASYMPTOMATIC CHRONIC CARRIER - A POTENTIAL HAZARD TO BLOOD RECIPIENTS - BLOOD BANK-BASED STUDY

BACKGROUND Blood transfusion is an effective mode of transmission of hepatitis C infection. Hepatitis C is an emerging infection in India, which was detected in 1989. US and Japan started screening for HCV in 1990, which...

COMPARISON OF 0.1% BUPIVACAINE WITH 2 MCG/ML FENTANYL AND 0.1% ROPIVACAINE WITH 2 MCG/ML FOR LABOUR ANALGESIA

BACKGROUND Epidural neuraxial blockade is an efficient and an easy method of administering labour analgesia without any adverse effects on the foetus. Labour analgesia thus helps the mother enjoy the delivery of her chil...

COMPARISON OF SEDATIVE AND HAEMODYNAMIC EFFECTS OF INTRAVENOUS DEXMEDETOMIDINE AND MIDAZOLAM COMBINATION AND INTRAVENOUS DEXMEDETOMIDINE IN CHILDREN UNDERGOING MAGNETIC RESONANCE IMAGING

BACKGROUND Sedation is a necessity for MR procedures conducted in children for adequate alleviation of anxiety, pain relief while securing IV access, and in order to avoid movements during the procedure. Dexmedetomidine,...

Download PDF file
  • EP ID EP608444
  • DOI 10.18410/jebmh/2018/723
  • Views 68
  • Downloads 0

How To Cite

Hareesh M. V. K, Sharma R. K. (2018). INDUCTION THERAPY IN RENAL TRANSPLANTATION WITH ANTITHYMOCYTE GLOBULIN AND BASILIXIMAB- A SINGLE CENTRE RETROSPECTIVE STUDY. Journal of Evidence Based Medicine and Healthcare, 5(52), 3545-3551. https://europub.co.uk/articles/-A-608444